CRIS Current Research Information System

CIANI, ELISABETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.196
AS - Asia 5.706
EU - Europa 4.554
AF - Africa 514
Continente sconosciuto - Info sul continente non disponibili 245
SA - Sud America 233
OC - Oceania 6
Totale 17.454
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.063
IT - Italia 1.786
SG - Singapore 1.580
VN - Vietnam 1.520
CN - Cina 1.339
GB - Regno Unito 698
DE - Germania 495
HK - Hong Kong 419
SE - Svezia 298
IN - India 215
NL - Olanda 213
FR - Francia 211
BR - Brasile 155
IE - Irlanda 151
BD - Bangladesh 145
RU - Federazione Russa 137
SC - Seychelles 136
TG - Togo 134
KR - Corea 122
UA - Ucraina 121
CI - Costa d'Avorio 105
FI - Finlandia 82
CH - Svizzera 77
JP - Giappone 76
ZA - Sudafrica 73
CA - Canada 68
JO - Giordania 53
BG - Bulgaria 51
ES - Italia 47
PH - Filippine 41
EE - Estonia 40
TR - Turchia 40
NG - Nigeria 36
AR - Argentina 33
AT - Austria 33
ID - Indonesia 30
BE - Belgio 29
MX - Messico 21
TH - Thailandia 21
IR - Iran 18
PL - Polonia 18
TW - Taiwan 16
JM - Giamaica 13
GR - Grecia 12
HR - Croazia 11
MY - Malesia 11
PK - Pakistan 11
IQ - Iraq 10
DK - Danimarca 9
EC - Ecuador 9
AE - Emirati Arabi Uniti 8
CO - Colombia 8
CL - Cile 7
PE - Perù 7
SA - Arabia Saudita 7
VE - Venezuela 7
AU - Australia 6
MA - Marocco 6
RO - Romania 6
CZ - Repubblica Ceca 5
LB - Libano 5
PT - Portogallo 5
SM - San Marino 5
TT - Trinidad e Tobago 5
DZ - Algeria 4
GT - Guatemala 4
NP - Nepal 4
UZ - Uzbekistan 4
BS - Bahamas 3
EG - Egitto 3
ET - Etiopia 3
HN - Honduras 3
KE - Kenya 3
MD - Moldavia 3
NI - Nicaragua 3
PY - Paraguay 3
UY - Uruguay 3
BB - Barbados 2
CR - Costa Rica 2
HU - Ungheria 2
IL - Israele 2
NO - Norvegia 2
OM - Oman 2
PA - Panama 2
TN - Tunisia 2
AI - Anguilla 1
AL - Albania 1
AM - Armenia 1
AO - Angola 1
AZ - Azerbaigian 1
BH - Bahrain 1
BO - Bolivia 1
BW - Botswana 1
BY - Bielorussia 1
BZ - Belize 1
CD - Congo 1
CG - Congo 1
CY - Cipro 1
GH - Ghana 1
IS - Islanda 1
Totale 17.193
Salva come PNG Salva come JPEG
Città #
Singapore 1.179
Ashburn 662
Bologna 635
Chandler 543
Southend 504
Fairfield 503
Hong Kong 375
Ho Chi Minh City 369
Hanoi 335
Santa Clara 314
Hefei 308
San Jose 301
Houston 256
Wilmington 234
Woodbridge 227
Seattle 216
Ann Arbor 210
Cambridge 188
Beijing 170
Council Bluffs 154
Dublin 150
Dong Ket 144
Boardman 138
Princeton 137
Lomé 134
Dallas 120
Seoul 109
Abidjan 105
Los Angeles 95
Milan 89
Turin 79
Frankfurt am Main 74
Jacksonville 72
Lauterbourg 71
New York 68
Bern 65
Helsinki 63
Nanjing 59
Tokyo 57
Bristol 55
Padova 55
Westminster 55
Amman 52
Falls Church 50
Berlin 49
Sofia 49
Buffalo 48
Redmond 47
Rome 44
Rimini 42
Da Nang 37
Haiphong 37
San Diego 36
Trento 36
Bengaluru 34
Marano 34
Munich 32
Abeokuta 31
Amsterdam 30
Islington 29
Shenyang 29
Brussels 28
Changsha 28
Tianjin 26
Guangzhou 25
Jinan 24
Argelato 23
Saint Petersburg 23
Chicago 22
Orem 22
Redondo Beach 22
Toronto 22
Johannesburg 21
Vienna 21
Hải Dương 20
Shanghai 19
São Paulo 19
Florence 18
Modena 17
Mülheim 17
Nanchang 17
Biên Hòa 15
Bolzano 15
Bonn 15
Dearborn 15
Falkenstein 15
Hebei 15
Jakarta 15
Jerez De La Frontera 15
Pune 15
Redwood City 15
San Francisco 15
Wuhan 15
Bremen 14
Castel Maggiore 14
Istanbul 14
Naples 14
Phoenix 14
Des Moines 13
London 13
Totale 11.133
Salva come PNG Salva come JPEG
Nome #
Inhibition of microglia over-activation restores neuronal survival and maturation in a mouse model of CDKL5 deficiency disorder 401
Beneficial Antioxidant Effects of Coenzyme Q10 in In Vitro and In Vivo Models of CDKL5 Deficiency Disorder 366
Age-related cognitive and motor decline in a mouse model of CDKL5 deficiency disorder is associated with increased neuronal senescence and death 353
CDKL5 protein substitution therapy rescues neurological phenotypes of a mouse model of CDKL5 disorder 340
Characterization of Perinatal Stem Cell Spheroids for the Development of Cell Therapy Strategy 338
AR-A014418-based dual Glycogen Synthase Kinase 3β/Histone Deacetylase inhibitors as potential therapeutics for Alzheimer's disease 326
Cardiac Functional and Structural Abnormalities in a Mouse Model of CDKL5 Deficiency Disorder 315
A GABAB receptor antagonist rescues functional and structural impairments in the perirhinal cortex of a mouse model of CDKL5 deficiency disorder 304
First in Class Dual Non-ATP-Competitive Glycogen Synthase Kinase 3β/Histone Deacetylase Inhibitors as a Potential Therapeutic to Treat Alzheimer’s Disease 303
Luteolin Treatment Ameliorates Brain Development and Behavioral Performance in a Mouse Model of CDKL5 Deficiency Disorder 299
Functional impairments in the perirhinal cortex of a mouse model of CDKL5 deficiency disorder are ameliorated by a GABAB receptor antagonist 294
Expression of a Secretable, Cell-Penetrating CDKL5 Protein Enhances the Efficacy of Gene Therapy for CDKL5 Deficiency Disorder 264
Heterozygous CDKL5 Knockout Female Mice Are a Valuable Animal Model for CDKL5 Disorder 261
Inhibition of microglia overactivation restores neuronal survival in a mouse model of CDKL5 deficiency disorder 258
Artificial protein and its applications 254
CDKL5 deficiency entails sleep apneas in mice 254
CDKL5 deficiency predisposes neurons to cell death through the deregulation of SMAD3 signaling (vol 29, pg 658, 2019) 252
Treatment with a GSK-3β/HDAC Dual Inhibitor Restores Neuronal Survival and Maturation in an In Vitro and In Vivo Model of CDKL5 Deficiency Disorder 246
HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder 245
Increased DNA Damage and Apoptosis in CDKL5-Deficient Neurons 244
Dietary restriction differentially protects from neurodegeneration in animal models of excitotoxicity. 236
Treatment with FRAX486 rescues neurobehavioral and metabolic alterations in a female mouse model of CDKL5 deficiency disorder 231
Lithium Restores Age Related Olfactory Impairment in the Ts65Dn Mouse Model of Down Syndrome 230
Age-related impairment of olfactory bulb neurogenesis in the Ts65Dn mouse model of Down syndrome 228
Epigallocatechin gallate: A useful therapy for cognitive disability in Down syndrome? 223
CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells 220
Functional and structural impairments in the perirhinal cortex of a mouse model of CDKL5 deficiency disorder are rescued by a TrkB agonist 219
Early Pharmacotherapy with Fluoxetine Rescues Dendritic Pathology in the Ts65Dn Mouse Model of Down Syndrome 218
Cyclic AMP-mediated regulation of transcription factor Lot1 expression in cerebellar granule cells. 217
The amyloid precursor protein (APP) triplicated gene impairs neuronal precursor differentiation and neurite development through two different domains in the Ts65Dn mouse model for down syndrome. 215
Treatment with the GSK3-beta inhibitor Tideglusib improves hippocampal development and memory performance in juvenile, but not adult, Cdkl5 knockout mice 213
Pharmacotherapy with sertraline rescues brain development and behavior in a mouse model of CDKL5 deficiency disorder 209
Neurochemical correlates of nicotine neurotoxicity on rat habenulo-interpeduncular cholinergic neurons. 207
APP-dependent alteration of GSK3β activity impairs neurogenesis in the Ts65Dn mouse model of Down syndrome. 207
Inhibition of GSK3β rescues hippocampal development and learning in a mouse model of CDKL5 disorder 207
Long-term effect of neonatal inhibition of APP gamma-secretase on hippocampal development in the Ts65Dn mouse model of Down syndrome 207
Early-onset brain alterations during postnatal development in a mouse model of CDKL5 deficiency disorder 207
APP-dependent up-regulation of Ptch1 underlies proliferation impairment of neural precursors in Down syndrome. 202
Postnatal neurogenesis in the dentate gyrus of the guinea pig 201
Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice 200
Widespread impairment of cell proliferation in the neonate Ts65Dn mouse, a model for Down syndrome. 199
Lactic acid bacteria as microbial cell factories for the in vivo delivery of therapeutic proteins as secretable TAT fusion products 193
Choline acetyltransferase activity at different ages in brain of Ts65Dn mice, an animal model for Down's syndrome and related neurodegenerative diseases. 190
Voluntary Running Improves Behavioral and Structural Abnormalities in a Mouse Model of CDKL5 Deficiency Disorder 189
Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome 188
Cell cycle elongation impairs proliferation of cerebellar granule cell precursors in the Ts65Dn Mouse, an animal model for Down syndrome. 187
Early Pharmacotherapy Restores Neurogenesis and Cognitive Performance in the Ts65Dn Mouse Model for Down Syndrome 186
Design, synthesis and pharmacological evaluation of multitarget GPR40 agonists/HDAC6 inhibitors for Alzheimer's disease 184
Sex differences in the hilar mossy cells of the guinea-pig before puberty. 181
Sex differences in the stereological parameters of the hippocampal dentate gyrus of the guinea pig before puberty 180
Loss of CDKL5 impairs survival and dendritic growth of newborn neurons by altering AKT/GSK-3β signaling. 179
Characterisation of sleep apneas and respiratory circuitry in mice lacking CDKL5 174
The green tea polyphenol epigallocatechin-3-gallate (EGCG) restores CDKL5-dependent synaptic defects in vitro and in vivo 174
Pharmacotherapy with Fluoxetine Restores Functional Connectivity from the Dentate Gyrus to Field CA3 in the Ts65Dn Mouse Model of Down Syndrome 173
Early-occurring proliferation defects in peripheral tissues of the Ts65Dn mouse model of Down syndrome are associated with patched1 over expression 172
Impact of environmental enrichment on neurogenesis in the dentate gyrus during the early postnatal period. 172
Timing of therapies for downsyndrome: The sooner, the better 172
Nitric oxide negatively regulates proliferation and promotes neuronal differentiation through N-Myc downregulation. 168
Prenatal pharmacotherapy rescues brain development in a Down's syndrome mouse model. 168
Effect of early isolation on signal transfer in the entorhinal cortex-dentate-hippocampal system 165
Proliferation of cerebellar precursor cells is negatively regulated by nitric oxide in newborn rat. 165
The place of choline acetyltransferase activity measurement in the "cholinergic hypothesis" of neurodegenerative diseases 164
Mapping pathological phenotypes in a mouse model of CDKL5 disorder. 161
Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome 159
CB1 cannabinoid receptors increase neuronal precursor proliferation through AKT/GSK-3{beta}/{beta}-catenin signaling 158
Lot1 is a key element of the pituitary adenylate cyclase-activating polypeptide (PACAP)/cyclic AMP pathway that negatively regulates neuronal precursor proliferation. 153
Widespread proliferation impairment and hypocellularity in the cerebellum of fetuses with Down syndrome. 151
Adult-Onset Deletion of CDKL5 in Forebrain Glutamatergic Neurons Impairs Synaptic Integrity and Behavior in Mice 149
Is it possible to improve neurodevelopmental abnormalities in Down syndrome? 147
Updating the dual role of brain nitric oxide in neurodegeneration/neuroprotection: understanding molecular mechanisms to devise drug approaches. 141
Heterozygous CDKL5 Knockout Female Mice Are a Valuable Animal Model for CDKL5 Disorder 141
Neonatal isolation impairs neurogenesis in the dentate gyrus of the guinea pig. 140
Site-specific abnormalities in the visual system of a mouse model of CDKL5 deficiency disorder 137
Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder 133
Role of nitric oxide in the regulation of neuronal proliferation, survival and differentiation. 131
Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome 130
null 130
Lithium restores neurogenesis in the subventricular zone of the Ts65Dn mouse, a model for Down sindrome 121
TATK-CDKL5 FUSION PROTEINS, COMPOSITIONS, FORMULATIONS, AND USE THEREOF 117
Therapeutic efficacy of the BKCa channel opener chlorzoxazone in a mouse model of Fragile X syndrome 116
Safety and efficacy of Igk-TATk-CDKL5 gene therapy in mosaic CDKL5 deficiency 115
Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice. 104
null 100
null 97
Autistic-relevant behavioral phenotypes of a mouse model of cyclin-dependent kinase-like 5 deficiency disorder 81
Sex differences in the hippocampal dentate gyrus of the guinea-pig before puberty 81
A cross-correction gene therapy approach for CDKL5 deficiency disorder improves the pathological phenotype of CDD patient-derived cortical organoids 64
Effects of gestational or neonatal treatment with alpha-difluoromethylornithine on ornithine decarboxylase and polyamines in developing rat brain and on adult rat neurochemistry 57
Sex differences in the hilar mossy cells of the guinea-pig before puberty 52
Nitric oxide regulates cGMP-dependent cAMP-responsive element binding protein phosphorylation and Bcl-2 expression in cerebellar neurons: Implication for a survival role of nitric oxide 51
Totale 17.454
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.384
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.384
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.376 0 71 117 117 135 102 62 80 71 107 261 253
2022/20232.213 173 366 105 260 162 196 55 125 365 51 166 189
2023/2024797 58 83 37 85 49 135 88 70 50 40 42 60
2024/20252.529 139 289 183 211 397 161 154 95 90 228 142 440
2025/20266.489 502 840 526 475 689 306 766 249 1.113 390 348 285
2026/2027386 208 178 0 0 0 0 0 0 0 0 0 0
Totale 17.454